# Why Biotech Talks About AI But Won't Pay for the Data It Needs

Page: https://stenobird.com/podcast/data-in-biotech-6628050/why-biotech-talks-about-ai-but-won-t-pay-for-the-data-it-needs
Text version: https://stenobird.com/podcast/data-in-biotech-6628050/why-biotech-talks-about-ai-but-won-t-pay-for-the-data-it-needs.md
Podcast: [Data in Biotech](https://stenobird.com/podcast/data-in-biotech-6628050)
Published: 2026-08-05T18:28:30+00:00
Episode link: https://www.corrdyn.com/
Audio file: https://downloads.pod.co/5fac40cd-043b-485f-838d-c63fa01ae1b2/ef6cb976-2ff8-4b53-8fa7-8e0887009dc7.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/data-in-biotech-6628050/episodes/why-biotech-talks-about-ai-but-won-t-pay-for-the-data-it-needs
Duration seconds: 3776

## Resource

Everyone in biotech agrees AI needs more data. Almost no one is willing to pay for it. If you're trying to build or buy a biotech AI model, you've hit the same wall: predictive performance depends on data your budget doesn't cover, and nobody in the field seems willing to close that gap. John Androsavich runs Ginkgo Datapoints, the bio AI data arm of Ginkgo Bioworks. He trained as an RNA scientist, spent years on the pharma side deciding which technologies were worth buying, and now sells the raw biological data everyone claims to want. Ross and John get into why biotech spends a fraction of what tech spends on data, how automation dropped ADME testing to $199 a compound, and what that unlocks for drug discovery pipelines and data science in biotech more broadly. You'll hear why single-cell foundation models don't scale the way the field expected, and how GPT-5 designed its own lab experiments inside an autonomous facility. This one's for data and analytics leaders in biotech who need a clearer read on where to spend on data generation, and where the field is still guessing. It's less useful if you're after a general AI overview with no biotech specifics. Key Takeaways - One Meta investment in a data-labelling vendor outweighs a full year of AI drug discovery venture funding combined, and dwarfs the entire single-cell data market. Biotech's data spend looks nothing like tech's. - Ginkgo's ADME-1 offering runs at roughly a tenth of standard pricing, which is changing when and how much companies test. Teams are now running full tier-one panels earlier instead of triaging molecules before they've generated the negative data models need. - A recent Microsoft Research paper found single-cell foundation model learning saturates at 200,000 to 2 million cells, out of a possibl…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/data-in-biotech-6628050/episodes/why-biotech-talks-about-ai-but-won-t-pay-for-the-data-it-needs/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/data-in-biotech-6628050/why-biotech-talks-about-ai-but-won-t-pay-for-the-data-it-needs.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.